Jasper CEO Highlights Briquilimab's Potential in CSU and CIndU
"Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma," said Jeet Mahal, President and CEO of Jasper. "We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients. We are finalizing dose selection for the Phase 2b portion of our planned Phase 2b/3 study in CSU where we will evaluate two efficacious doses versus placebo to demonstrate the differentiated profile based on briquilimab's unique biological properties. We remain on track to commence patient enrollment in the second half of 2026, pending capital availability."
Trade with 70% Backtested Accuracy
Analyst Views on JSPR
About JSPR
About the author
Jasper Therapeutics Reports Fiscal Year 2025 Results and Corporate Update
- Clinical Data Highlights: Jasper Therapeutics reported that 67% of patients in the BEACON study for chronic spontaneous urticaria achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points, indicating briquilimab's significant efficacy and potential to increase market share in this area.
- Financial Performance: As of December 31, 2025, Jasper's cash and cash equivalents totaled $28.7 million, while R&D expenses reached $11.4 million, resulting in a net loss of $75.8 million for the fiscal year 2025, highlighting financial pressures that may impact future clinical trial progress.
- Management Changes: Jeet Mahal was appointed as CEO to lead the company into a new phase of clinical growth, indicating a significant strategic shift that could influence investor confidence moving forward.
- Future Outlook: Jasper plans to initiate its Phase 2b/3 clinical trial for chronic spontaneous urticaria in the second half of 2026, although challenges related to capital availability remain; successful advancement could present new growth opportunities for the company.
Jasper Therapeutics Q4 Earnings Beat Expectations with Significant Cash Reserves
- Earnings Highlights: Jasper Therapeutics reported a Q4 GAAP EPS of -$0.32, beating market expectations by $0.48, indicating an improvement in financial performance that may boost investor confidence.
- Cash Reserves: As of December 31, 2025, Jasper Therapeutics had cash and cash equivalents totaling $28.7 million, providing ample funding for future R&D and operations, thereby enhancing its financial stability.
- New CEO Appointment: The recent appointment of a new CEO at Jasper Therapeutics is expected to bring a fresh strategic direction and management style, potentially driving growth in the competitive biopharmaceutical market.
- Research Data Update: The company updated data from its BEACON and open-label extension studies in chronic urticaria, demonstrating its ongoing efforts in the treatment space and potential market opportunities that may attract more investor interest.
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
UBS Initiates Coverage of Jasper Therapeutics Inc with Neutral Rating and $1.50 Price Target
Company Overview: Jaspar Therapeutics is a biopharmaceutical company focused on developing innovative therapies.
Recent Coverage: The company has received neutral ratings in recent analyses, indicating a cautious outlook from analysts.
Target Price: Analysts have set a target price of $1.50 for Jaspar Therapeutics' stock.
Market Position: The neutral rating suggests that while there is potential, there are also risks that investors should consider.
Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
Jasper Stock Soars Following Positive Results from New Asthma Study
Briquilimab Study Results: Jasper Therapeutics released preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced sputum eosinophils and improved lung function indicators in adults with allergic asthma, demonstrating a favorable safety profile.
Eosinophil Reduction: Treatment with briquilimab led to substantial decreases in sputum eosinophil levels before and after allergen challenges, indicating its potential effectiveness in managing allergic asthma symptoms.
BEACON Cohort Investigation: Jasper completed an internal investigation into the lack of clinical response in the BEACON study cohorts, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug itself.
Stock Performance: Following the positive study results, Jasper Therapeutics' shares increased by 8.72%, reaching $1.87 at the time of publication.
Jasper Therapeutics Reports Fiscal Year 2025 Results and Corporate Update
- Clinical Data Highlights: Jasper Therapeutics reported that 67% of patients in the BEACON study for chronic spontaneous urticaria achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points, indicating briquilimab's significant efficacy and potential to increase market share in this area.
- Financial Performance: As of December 31, 2025, Jasper's cash and cash equivalents totaled $28.7 million, while R&D expenses reached $11.4 million, resulting in a net loss of $75.8 million for the fiscal year 2025, highlighting financial pressures that may impact future clinical trial progress.
- Management Changes: Jeet Mahal was appointed as CEO to lead the company into a new phase of clinical growth, indicating a significant strategic shift that could influence investor confidence moving forward.
- Future Outlook: Jasper plans to initiate its Phase 2b/3 clinical trial for chronic spontaneous urticaria in the second half of 2026, although challenges related to capital availability remain; successful advancement could present new growth opportunities for the company.
Jasper Therapeutics Q4 Earnings Beat Expectations with Significant Cash Reserves
- Earnings Highlights: Jasper Therapeutics reported a Q4 GAAP EPS of -$0.32, beating market expectations by $0.48, indicating an improvement in financial performance that may boost investor confidence.
- Cash Reserves: As of December 31, 2025, Jasper Therapeutics had cash and cash equivalents totaling $28.7 million, providing ample funding for future R&D and operations, thereby enhancing its financial stability.
- New CEO Appointment: The recent appointment of a new CEO at Jasper Therapeutics is expected to bring a fresh strategic direction and management style, potentially driving growth in the competitive biopharmaceutical market.
- Research Data Update: The company updated data from its BEACON and open-label extension studies in chronic urticaria, demonstrating its ongoing efforts in the treatment space and potential market opportunities that may attract more investor interest.
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
UBS Initiates Coverage of Jasper Therapeutics Inc with Neutral Rating and $1.50 Price Target
Company Overview: Jaspar Therapeutics is a biopharmaceutical company focused on developing innovative therapies.
Recent Coverage: The company has received neutral ratings in recent analyses, indicating a cautious outlook from analysts.
Target Price: Analysts have set a target price of $1.50 for Jaspar Therapeutics' stock.
Market Position: The neutral rating suggests that while there is potential, there are also risks that investors should consider.
Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment
- Leadership Change: Jasper Therapeutics has appointed Jeet Mahal as CEO, succeeding Ronald Martell, who joined in 2022; Mahal brings over 30 years of life sciences experience and will drive the development of briquilimab, enhancing the company's competitiveness in chronic urticaria.
- Clinical Research Update: Jasper will host an investor webinar on January 8, 2026, to present updated data from the BEACON study and open-label extension studies, aiming to boost investor confidence and increase focus on briquilimab.
- Product Development Strategy: Mahal emphasized briquilimab's potential in chronic spontaneous urticaria and inducible urticaria, planning to efficiently complete current studies and lay the groundwork for future development, which is expected to provide more effective treatment options for patients.
- Former CEO Contributions: Ronald Martell successfully pivoted briquilimab's development towards allergic and immunological diseases during his tenure, establishing a foundation for clinical proof of concept that supports the company's future growth.
Jasper Stock Soars Following Positive Results from New Asthma Study
Briquilimab Study Results: Jasper Therapeutics released preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced sputum eosinophils and improved lung function indicators in adults with allergic asthma, demonstrating a favorable safety profile.
Eosinophil Reduction: Treatment with briquilimab led to substantial decreases in sputum eosinophil levels before and after allergen challenges, indicating its potential effectiveness in managing allergic asthma symptoms.
BEACON Cohort Investigation: Jasper completed an internal investigation into the lack of clinical response in the BEACON study cohorts, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug itself.
Stock Performance: Following the positive study results, Jasper Therapeutics' shares increased by 8.72%, reaching $1.87 at the time of publication.
